Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment

No abstract is available for this paper.

• Publication year

  2009

• Venue

  BJU International

• Publication date

  2009-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1464-410X.2009.08675.xPMID 19522864
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention

  2009cited by this paper
• Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome

  2009cited by this paper
• Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder.

  2008cited by this paper
• Followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus Calmette-Guerin or placebo.

  2008cited by this paper
• [Structure and function of suburothelial myofibroblasts in the human urinary bladder under normal and pathological conditions].

  2007cited by this paper
• Neural upregulation in interstitial cystitis.

  2007cited by this paper
• The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis.

  2007cited by this paper
• Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis.

  2007cited by this paper
• The role of the bladder surface in interstitial cystitis/painful bladder syndrome.

  2007cited by this paper
• Struktur und Funktion der suburothelialen Myofibroblasten in der humanen Harnblase unter normalen und pathologischen Bedingungen

  2007cited by this paper
• The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis.

  2007cited by this paper
• Augmented extracellular ATP signaling in bladder urothelial cells from patients with interstitial cystitis.

  2006cited by this paper
• VAS（Visual Analogue Scale）を用いた高校生の月経随伴症状の評価

  2006cited by this paper
• Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study.

  2006cited by this paper
• Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders

  2006cited by this paper
• NGF and GDNF differentially regulate TRPV1 expression that contributes to development of inflammatory thermal hyperalgesia

  2004cited by this paper
• Increased nerve growth factor expression triggers bladder overactivity.

  2004cited by this paper
• Pathology of interstitial cystitis

  2003cited by this paper
• Alterations in neuropeptide expression in lumbosacral bladder pathways following chronic cystitis.

  2001cited by this paper
• The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor.

  2001cited by this paper
• Alterations in spinal cord Fos protein expression induced by bladder stimulation following cystitis.

  2000cited by this paper
• The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study.

  1999cited by this paper
• Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of the urinary bladder.

  1999cited by this paper
• Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients.

  1999cited by this paper
• Rapid increase of NGF, BDNF and NT‐3 mRNAs in inflamed bladder

  1998cited by this paper
• Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis.

  1997cited by this paper
• Sensitisation of visceral afferents by nerve growth factor in the adult rat

  1996cited by this paper
• Neural input regulates tissue NGF and growth of the adult rat urinary bladder.

  1994cited by this paper
• Pathology of interstitial cystitis.

  1994cited by this paper
• Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function.

  1991cited by this paper

• Beyond Osteoarthritis: Emerging Applications of Anti-NGF Monoclonal Antibodies in Pain Management in Dogs and Cats

  2025cites this paper
• Platelet-Rich Plasma in Interstitial Cystitis/Bladder Pain Syndrome: A Systematic Review and Meta-Analysis

  2025cites this paper
• The Role of Biomarkers in the Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome: What Does Current Evidence Reveal?

  2025cites this paper
• Characteristic genes and immune landscape of interstitial cystitis

  2025cites this paper
• Bladder Trigone as a Sensory Hub: A Narrative Review

  2025cites this paper
• Integrating biomarker clustering for improved diagnosis of interstitial cystitis/bladder pain syndrome: a review

  2025cites this paper
• The integration of biomarkers and patient-reported outcomes improves prediction of interstitial cystitis syndrome

  2025cites this paper
• Platelet-rich plasma attenuates the UPEC-induced cystitis via inhibiting MMP-2,9 activities and downregulation of NGF and VEGF in Canis Lupus Familiaris model

  2024cites this paper
• Definition Change and Update of Clinical Guidelines for Interstitial Cystitis and Bladder Pain Syndrome

  2024cites this paper
• Changes in nerve growth factor signaling in female mice with cyclophosphamide-induced cystitis

  2023cites this paper
• Current optimal pharmacologic therapies for overactive bladder

  2023cites this paper
• Interstitial Cystitis/Bladder Pain Syndrome: Role of Bladder Inflammation in Bladder Function

  2023cites this paper
• Can We Use Urinary Cytokine/Chemokine Analysis in Discriminating Ulcer-Type Interstitial Cystitis/Bladder Pain Syndrome?

  2022cites this paper
• S2k-Leitlinie Diagnostik und Therapie der interstitiellen Zystitis (IC/BPS)

  2022cites this paper
• Biomarkers in bladder pain syndrome: A new narrative

  2022cites this paper
• Liposome-Encapsulated Botulinum Toxin A in Treatment of Functional Bladder Disorders

  2022cites this paper
• Nanotechnology as a tool to advance research and treatment of non-oncologic urogenital diseases

  2022cites this paper
• Preliminary Exploration of a New Therapy for Interstitial Cystitis/Bladder Pain Syndrome: Botulinum Toxin A Combined with Sapylin

  2022cites this paper
• Stress-Induced Changes in Trophic Factor Expression in the Rodent Urinary Bladder: Possible Links With Angiogenesis

  2022cites this paper
• Urinary Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome

  2021influential citation
• A Systematic Review of Therapeutic Approaches Used in Experimental Models of Interstitial Cystitis/Bladder Pain Syndrome

  2021cites this paper
• Components of the Endogenous Cannabinoid System as Potential Biomarkers for Interstitial Cystitis/Bladder Pain Syndrome

  2021cites this paper
• Brain-derived neurotrophic factor, nerve growth factor, and high sensitivity C-reactive protein levels in urine in overactive bladder patients: a meta-analysis

  2021cites this paper
• Recurrent urinary tract infection in women and overactive bladder – Is there a relationship?

  2020cites this paper
• Nerve Growth Factor Signaling and Its Contribution to Pain

  2020cites this paper
• The Urothelium, the urinary microbioma and men LUTS: a systematic review.

  2020cites this paper
• Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders—From Bench to Bedside

  2020cites this paper
• Clinical guidelines for interstitial cystitis/bladder pain syndrome

  2020cites this paper
• Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders

  2020cites this paper
• Application of Adult and Pluripotent Stem Cells in Interstitial Cystitis/Bladder Pain Syndrome Therapy: Methods and Perspectives

  2020cites this paper
• The diagnostic value of nerve growth factor and c-reactive protein in patients with interstitial cystitis / painful bladder syndrome

  2020cites this paper
• Relationship of Bladder Pain With Clinical and Urinary Markers of Neuroinflammation in Women With Urinary Urgency Without Urinary Incontinence.

  2020cites this paper
• Treatment with low-energy shock wave alleviates pain in an animal model of uroplakin 3A-induced autoimmune interstitial cystitis/painful bladder syndrome

  2019cites this paper
• S 2 K guideline Diagnosis and Treatment of Interstitial Cystitis ( IC / BPS )

  2019cites this paper
• Partners in Crime: NGF and BDNF in Visceral Dysfunction

  2019cites this paper
• Effect of Water Avoidance Stress on serum and urinary NGF levels in rats: diagnostic and therapeutic implications for BPS/IC patients

  2019cites this paper
• Nerve Growth Factor Levels are Associated with Overactive Bladder Symptoms and Long‐Term Treatment Outcome after Transurethral Resection of the Prostate in Patients with Benign Prostatic Hyperplasia

  2018cites this paper
• The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI‐RS 2017 think thank, Bristol

  2018cites this paper
• Diagnostic value of urinary CXCL10 as a biomarker for predicting Hunner type interstitial cystitis

  2018cites this paper
• Current Concepts in Urinary Biomarkers for Overactive Bladder: What Is the Evidence?

  2017cites this paper
• Nerve growth factor does not seem to be a biomarker for neurogenic lower urinary tract dysfunction after spinal cord injury

  2017cites this paper
• Potential Biomarkers for Diagnosis of Overactive Bladder Patients: Urinary Nerve Growth Factor, Prostaglandin E2, and Adenosine Triphosphate

  2017cites this paper
• Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome

  2017cites this paper
• Current Understanding of Cannabinoids and Detrusor Overactivity

  2017cites this paper
• Tibial Nerve Stimulation for the management of overactive bladder and the measurement of urinary neurotrophins as a biomarker of response to treatment

  2017cites this paper
• Urothelial dysfunction and sensory protein expressions in patients with urological or systemic diseases and hypersensitive bladder

  2017cites this paper
• Update on Urinary Tract Markers in Interstitial Cystitis/Bladder Pain Syndrome

  2016cites this paper
• Biomarkers for interstitial cystitis/painful bladder syndrome "Urinary elevation of proteins associated with interstitial cystitis/painful bladder syndrome may be due to lesser dilution of proteins shed into urine or due to lower levels of proteases in urine compared to plasma."

  2016cites this paper
• Hydrodistension plus Onabotulinumtoxin A in bladder pain syndrome refractory to conservative treatments.

  2016cites this paper
• Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis—Different Mechanisms of Action of Botox on Bladder Dysfunction?

  2016cites this paper
• Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action

  2016cites this paper
• Evidence for the Role of Mast Cells in Cystitis-Associated Lower Urinary Tract Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study

  2016cites this paper
• Elevated level of nerve growth factor in the bladder pain syndrome/interstitial cystitis: a meta-analysis

  2016cites this paper
• Intravesical Botulinum Toxin A Injections for Bladder Pain Syndrome/Interstitial Cystitis: A Systematic Review and Meta-Analysis of Controlled Studies

  2016cites this paper
• Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease

  2016cites this paper
• Biomarkers for Interstitial Cystitis/Painful Bladder Syndrome

  2016cites this paper
• Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015

  2016cites this paper
• A novel method for assessing bladder‐related pain reveals the involvement of nerve growth factor in pain associated with cyclophosphamide‐induced chronic cystitis in mice

  2016cites this paper
• A data science approach to candidate gene selection of pain regarded as a process of learning and neural plasticity

  2016cites this paper
• Anti-NGF monoclonal antibody muMab 911 does not deplete neurons in the superior cervical ganglia of young or old adult rats.

  2016cites this paper
• Advances in intravesical therapy for urinary tract disorders

  2016cites this paper
• Hydrodistension plus Onabotulinumtoxin A in bladder pain syndrome refractory to conservative treatments.

  2016cites this paper
• Biomarkers for patients with interstitial cystitis/bladder pain syndrome

  2015cites this paper
• Current guidelines in the management of interstitial cystitis

  2015cites this paper
• Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response

  2015cites this paper
• Anesthetic Bladder Hydrodistention Is Superior to Superior Hypogastric Plexus Neurolysis in Treatment of Interstitial Cystitis-bladder Pain Syndrome: A Prospective Randomized Trial.

  2015cites this paper
• Urinary bladder inflammation induces changes in urothelial nerve growth factor and TRPV1 channels

  2015cites this paper
• Intravesical gemcitabine treatment: repercussions on normal bladder function.

  2015cites this paper
• Editorial Comment from Dr Tomoe to Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response

  2015cites this paper
• The role of endocannabinoids and their receptors on the regulation of bladder function and detrusor overactivity

  2015cites this paper
• O’Leary-Sant Symptom Index Predicts the Treatment Outcome for Onabotulinumtoxin A Injections for Refractory Interstitial Cystitis/Bladder Pain Syndrome

  2015cites this paper
• Pathophysiology of interstitial cystitis/bladder pain syndrome

  2015cites this paper
• The role of inflammatory mediators in the overactive and bladder pain syndromes

  2015cites this paper
• Artemin Immunotherapy Is Effective in Preventing and Reversing Cystitis-Induced Bladder Hyperalgesia via TRPA1 Regulation.

  2015cites this paper
• Fibrin-based microsphere reservoirs for delivery of neurotrophic factors to the brain.

  2015cites this paper
• Mast Cell-Mediated Mechanisms of Nociception

  2015cites this paper
• Urinary Nerve Growth Factor Could Be a Biomarker for Interstitial Cystitis/Painful Bladder Syndrome: A Meta-Analysis

  2014cites this paper
• Ulcerative and nonulcerative forms of bladder pain syndrome/interstitial cystitis do not differ in symptom intensity or response to onabotulinum toxin A.

  2014cites this paper
• Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis

  2014cites this paper
• Urinary NGF, TGF-β1, TIMP-2 and bladder wall thickness predict neurourological findings in children with myelodysplasia.

  2014cites this paper
• Decrease of Urinary Nerve Growth Factor but Not Brain-Derived Neurotrophic Factor in Patients with Interstitial Cystitis/Bladder Pain Syndrome Treated with Hyaluronic Acid

  2014cites this paper
• BDNF and ARTEMIN are increased in drug-naïve non-depressed GAD patients: Preliminary data

  2014cites this paper
• Urinary nerve growth factor correlates with the severity of urgency and pain

  2014cites this paper
• Mast cells in chronic inflammation, pelvic pain and depression in women

  2014cites this paper
• A multicentre, prospective, randomised, double-blind study to measure the treatment effectiveness of abobotulinum A (AboBTXA) among women with refractory interstitial cystitis/bladder pain syndrome

  2014cites this paper
• Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder

  2014cites this paper
• Increased Severity of Inflammation Correlates with Elevated Expression of TRPV1 Nerve Fibers and Nerve Growth Factor on Interstitial Cystitis/Bladder Pain Syndrome

  2014cites this paper
• Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride

  2014cites this paper
• Lower Urinary Tract Disease and Their Objective and Noninvasive Biomarkers

  2014cites this paper
• Bladder pain syndrome: contemporary management and future strategies

  2014cites this paper
• A Multicentre, Prospective, Randomized, Double-Blind Study To Measure the Treatment 2 effectiveness of Abobotulinum A (BTXA) among Women with Refractory interstitial 3 cystitis/bladder pain syndrome.

  2013cites this paper
• Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens

  2013cites this paper
• Follow-up protein profiles in urine samples during the course of obstructive feline idiopathic cystitis.

  2013cites this paper
• [Effectiveness of acupuncture and moxibustion therapy for the treatment of refractory interstitial cystitis].

  2013cites this paper
• Sciatic nerve regeneration is not inhibited by anti-NGF antibody treatment in the adult rat.

  2013cites this paper
• Potential urine and serum biomarkers for patients with overactive bladder and interstitial cystitis/bladder pain syndrome

  2013cites this paper
• New diagnostic techniques for functional lower urinary tract disorders

  2013cites this paper
• Chronic Prostatitis/Chronic Pelvic Pain Syndrome: What Are the Starting and Worsening Factors?

  2013cites this paper
• Cyclophosphamide-induced cystitis reduces ASIC channel but enhances TRPV1 receptor function in rat bladder sensory neurons.

  2013cites this paper
• Increased Pro-Inflammatory Cytokines, C-Reactive Protein and Nerve Growth Factor Expressions in Serum of Patients with Interstitial Cystitis/Bladder Pain Syndrome

  2013cites this paper